- Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Patients (ELICE-BD)
- Synapse-BD Study (Coming Soon)
- Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
- Neuropsychology and treatment response in depression
1. Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Patients (ELICE-BD)
3. Efficacy of Cariprazine in Improving Cognitive Functioning in Euthymic patients with Bipolar I Disorder: A Proof of Concept Randomized, Double Blind Placebo Controlled Trial
Principal investigator: Dr. Lakshmi Yatham, Professor of Psychiatry, UBC
Funding: Grant – Allergen Inc.
Years: 2021-2026; UBC CREB: (#H20-01293)
This study is tests whether adding Cariprazine to current medication in people diagnosed with bipolar disorder improves cognitive abilities (for example, attention, memory) over a 6-week period compared to a placebo.
Cariprazine is a medication approved for the treatment of bipolar disorder in the USA which may also help with any associated cognitive difficulties.
We are looking for patients diagnosed with bipolar disorder who are not currently experiencing a mood episode, are 19-65 years of age, and are clinically stable on current medication.
The study involves clinical questionnaires, and tests of memory, reasoning and attention.
Compensation will be provided for participation.
The study has been approved by the UBC Ethics Committee (# H20-01293). For more information, please email firstname.lastname@example.org or call Jayasree at 604-822-3769.
More information can also be found at https://www.vchri.ca/research-study/assessing-role-cariprazine-improving-cognition-euthymic-bipolar-patients-carpz-01 and ClinicalTrials.gov.